866-997-4948(US-Canada Toll Free)

AMG 386 (Ovarian Cancer) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Ovarian Cancer

No. of Pages : 34 Pages

 

GlobalDatas pharmaceuticals report, "AMG 386 (Ovarian Cancer) - Analysis and Forecasts to 2020 provides AMG 386 sales forecasts for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US, EU and Japan (seven major markets)
  • Analysis and review of AMG 386 including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of AMG 386 including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2015-2020 for AMG 386 in the seven major markets

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Ovarian Cancer 4
2.2 Ovarian Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Age 6
2.4.2 Inherited Gene Mutations 6
2.4.3 A Previous Cancer Diagnosis 6
2.4.4 Early Menstruation or Late menopause 7
2.4.5 Family History of Ovarian Cancer 7
2.5 GlobalData Market Forecasts Report Guidance 8


3 Ovarian Cancer: Market Characterization 9
3.1 Ovarian Cancer Market 9
3.2 Ovarian Cancer Market Forecasts and CAGR 9
3.3 Drivers for Ovarian Cancer Market 10
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 12
3.3.4 Emergence of Targeted Drugs 12
3.3.5 Recurrence of Tumor 12
3.3.6 Low Initial Diagnosis Rate 12


4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer 13


5 AMG 386 16
5.1 Introduction 16
5.2 Mechanism of Action 16
5.3 Clinical Studies 16
5.4 Factors Affecting Sales of AMG 386 17
5.4.1 First Mover Advantage 17
5.4.2 AMG 386 in Combination with Avastin 17
5.4.3 Safety and Toxicity Profile 17
5.5 Drug Evaluation 18
5.5.1 Drug Risk Benefit Score 18
5.5.2 Relative Efficacy 18
5.5.3 Safety 18
5.5.4 Compliance 18
5.5.5 Dosing Convenience 18
5.5.6 Intensity of Competition 18
5.6 Sales Forecasts 19
5.6.1 Target Patient Pool of AMG 386 19
5.6.2 Dosing 19
5.6.3 Market Penetration 20
5.6.4 Annual Cost of Therapy 20
5.6.5 Sales Projections of AMG 386 21


6 Ovarian Cancer Market: Appendix 30
6.1 Market Definitions 30
6.2 Abberiviations 30
6.3 Research Methodology 30
6.3.1 Coverage 30
6.3.2 Secondary Research 30
6.3.3 Forecasting 31
6.3.4 Number of Patients Approved to take the Drug 31
6.3.5 Net Penetration of Drug 31
6.3.6 Net Annual Dosing 32
6.3.7 Annual Cost of Therapy 33
6.3.8 Primary Research 33
6.3.9 Expert Panels 33
6.4 Contact Us 33
6.5 Disclaimer 33
6.6 Sources 34

List of Table


Table 1: Ovarian Cancer, Incidences and Mortality, 20082030 6
Table 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 9
Table 3: Detailed TNM Classification 14
Table 4: Drug Risk Benefit Score of AMG 386 18
Table 5: Annual Cost of Therapy of AMG 386, 2015 20
Table 6: AMG 386, Ovarian Cancer, Global, Sales Forecasts ($m), 20152020 21
Table 7: AMG 386, Ovarian Cancer, The US, Sales Forecasts ($m), 20152020 22
Table 8: AMG 386, Ovarian Cancer, The UK, Sales Forecasts ($m), 20152020 23
Table 9: AMG 386, Ovarian Cancer, France, Sales Forecasts ($m), 20152020 24
Table 10: AMG 386, Ovarian Cancer, Germany, Sales Forecasts ($m), 20152020 25
Table 11: AMG 386, Ovarian Cancer, Italy, Sales Forecast ($m), 20152020 26
Table 12: AMG 386, Ovarian Cancer, Spain, Sales Forecasts ($m), 20152020 27
Table 13: AMG 386, Ovarian Cancer, Japan, Sales Forecasts ($m), 20152020 28

List of Chart


Figure 1: Distribution by Incidence and Mortality, Most Frequently Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 9
Figure 3: Ovarian Cancer, Worldwide, Incidence (in million), 2008-2030 10
Figure 4: Oncology, Worldwide, Incidence (in million), 2008-2030 11
Figure 5: Ovarian Cancer, Worldwide, Mortality (in million), 2008-2030 11
Figure 6: Broad Classification of Ovarian Cancer 13
Figure 7: Classification of Ovarian Cancer 15
Figure 8: Drug Model Diagram of AMG 386 19
Figure 9: AMG 386, Ovarian Cancer, Global, Sales Forecasts ($m), 20152020 21
Figure 10: AMG 386, Ovarian Cancer , The US, Sales Forecasts ($m), 20152020 22
Figure 11: AMG 386, Ovarian Cancer, The UK, Sales Forecasts ($m), 20152020 23
Figure 12: AMG 386, Ovarian Cancer, France, Sales Forecasts ($m), 20152020 24
Figure 13: AMG 386, Ovarian Cancer, Germany, Sales Forecasts ($m), 20152020 25
Figure 14: AMG 386, Ovarian Cancer, Italy, Sales Forecasts ($m), 20152020 26
Figure 15: AMG 386, Ovarian Cancer, Spain, Sales Forecasts ($m), 20152020 27
Figure 16: AMG 386, Ovarian Cancer, Japan, Sales Forecasts ($m), 20152020 28
Figure 17: AMG 386, Ovarian Cancer, Global, Sales Distribution by Country (%), 2020 29
Figure 18: Drug Model Diagram 32
Figure 19: Patients Approved for the Drug 32

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *